Evidence map›Paper›PMID 35914611›Full record

ArticleThe Journal of infection2022

Remdesivir modifies interferon response in hospitalized COVID-19 patients.

Sarah L Murphy, Bente Halvorsen, Andreas Barratt-Due, Anne Ma Dyrhol-Riise, Pål Aukrust, Marius Trøseid, Tuva B Dahl

Open access · hybridAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sarah L MurphyInstitute of Clinical Medicine, University of Oslo, Oslo 0318, Norway; Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway.
Bente HalvorsenInstitute of Clinical Medicine, University of Oslo, Oslo 0318, Norway; Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway.
Andreas Barratt-DueDivision of Critical Care and Emergencies, Oslo University Hospital, Oslo, Norway; Department of Immunology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Anne Ma Dyrhol-RiiseInstitute of Clinical Medicine, University of Oslo, Oslo 0318, Norway; Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway.
Pål AukrustInstitute of Clinical Medicine, University of Oslo, Oslo 0318, Norway; Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Marius TrøseidInstitute of Clinical Medicine, University of Oslo, Oslo 0318, Norway; Research Institute for Internal Medicine, Oslo University Hospital Rikshospitalet, University of Oslo, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Tuva B DahlInstitute of Clinical Medicine, University of Oslo, Oslo 0318, Norway; Division of Critical Care and Emergencies, Oslo University Hospital, Oslo, Norway. Electronic address: t.b.dahl@medisin.uio.no.
Oslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentAdenosine MonophosphateAlanineAntiviral AgentsHumansInterferonsAdenosine MonophosphateAlanineAntiviral AgentsInterferonsremdesivir

Identifiers

PMID35914611
PMCPMC9338165
OpenAlexW4288808873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.